{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-002557","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2026-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.985817+00:00","generated_at":"2026-05-16T09:54:03.330599+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vivos Therapeutics enters $5.5M convertible note with V-Co, initial $900k funded","bullets":["Note up to $5.5M principal (incl. 10% OID) from V-Co Investors 3 LLC, affiliate of existing investor New Seneca Partners.","Initial $900k funded; additional advances possible until Feb 16, 2026 outside date for proposed equity financing.","Principal converts dollar-for-dollar into equity instruments of proposed Subsequent Financing; no interest unless default (then 15%).","Company expects to close $5.5M equity financing by Feb 16, 2026; note supports that process."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-002557","json":"https://secwatch.observer/filing/0001493152-26-002557.json","markdown":"https://secwatch.observer/filing/0001493152-26-002557.md","text":"https://secwatch.observer/filing/0001493152-26-002557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226002557/0001493152-26-002557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226002557/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:54:03.330599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f4463fe727f7ba66fca9fb011dd5b6ce1d5aa385","claim":"Vivos Therapeutics, Inc. entered into Note with V-Co Investors 3 LLC valued at up to $5,500,000 (effective 2026-01-15).","evidence_excerpt":"On January 15, 2026, Vivos Therapeutics, Inc. (the “ Company ”) entered into an unsecured convertible promissory note in favor of V-Co Investors 3 LLC (“ V-Co ”) in the maximum principal amount of up to $5,500,000 (the “ Note ” and the maximum principal amount, inclusive of the original issuance discount described below, the “ Maximum Principal ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226002557/0001493152-26-002557-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"V-Co Investors 3 LLC"},{"label":"Value","value":"up to $5,500,000"},{"label":"Effective","value":"2026-01-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}